2004 partnership included two early-stage candidates and bifeprunox, which received a not approvable letter in August 2007.
Wyeth Pharmaceuticals has ended its development and commercialization collaboration with Solvay Pharmaceuticals in the field of neuroscience. The agreement inked in 2004 included bifeprunox and two early-stage compounds.
Wyeth says that the opportunity for bifeprunox, an atypical antipsychotic, would not have sufficient commercial value for the two companies to share. In August 2007, FDA dismissed the firms’ NDA covering the acute treatment of schizophrenia or the maintenance of stable adult patients. At the time the not approvable letter was received, the companies said they would meet with the FDA for further discussions.
As per the termination, all development and commercialization rights in North America for bifeprunox and global rights for the other compounds will revert to Solvay Pharmaceuticals. Bifeprunox is currently in a Phase II trial as a treatment for bipolar disorder.